文献速递乳腺癌放疗放疗物理与技术

乳腺癌再程放疗实践模式:ReCOG国际调查

Breast Cancer Reirradiation Practice Patterns: An International Survey From the Reirradiation Collaborative Group (ReCOG).
PubMed 文献 · Pract Radiat Oncol · 2026-05-27

本研究通过ReCOG国际调查评估乳腺癌再程放疗的当代临床实践与知识缺口。

要点

  • 再程放疗最常见顾虑为既往放疗所致纤维化或淋巴水肿风险(40%)。
  • 常规分割45-60 Gy是最常选方案,其次为中度大分割40 Gy/15次。
  • 80%受访者在有既往DICOM数据时进行计划叠加,但方法各异。

核心结论

  • 乳腺癌再程放疗实践存在显著异质性,需标准化临床指南和实用工具支持患者选择、技术计划和器官剂量指导。

研究设计与样本

  • 受访者来自欧洲(n=19)、北美(n=14)和其他地区(n=4),代表32个可识别机构。

主要发现

  • 不提供再程放疗最常见原因为既往放疗所致纤维化或淋巴水肿高风险(40%)、短复发间隔(33%)和有限预期寿命(17%)。
  • 再程放疗后影响生活质量的最主要毒性为纤维化(31%)、疼痛(17%)和手臂淋巴水肿(14%)。
  • 最常选方案为常规分割45-60 Gy(1.8-2 Gy/次,23-30次),其次为中度大分割40 Gy/15次。
  • 外照射光子技术为主,IMRT/VMAT首选,质子和近距离治疗选择性使用,热疗使用有限(n=7)。
  • 80%受访者在有既往DICOM数据时进行计划叠加,但具体方法各异;臂丛、心脏、肺和皮肤的器官剂量指导最常用,但阈值差异大。

关键数值与推荐

  • 常规分割45-60 Gy(1.8-2 Gy/次,23-30次)为最常选再程放疗方案。
  • 中度大分割40 Gy/15次为次常选方案。
  • 一名受访者报告使用40-50 Gy(1.25-1.5 Gy/次,每日两次)方案。
  • 前三知识缺口:长期毒性和肿瘤结局数据、标准化验证的器官剂量指导、最佳再程放疗剂量分割共识及前瞻性试验缺乏。

临床怎么用

  • 再程放疗决策需综合评估既往放疗毒性风险、复发间隔和预期寿命。
  • 计划时应尽可能利用既往DICOM数据进行剂量叠加,并关注臂丛、心脏、肺和皮肤剂量。
  • 优先选择IMRT/VMAT等光子外照射技术,质子和近距离治疗可选择性使用。

局限性

  • 调查基于问卷,存在主观报告偏倚。
  • 未报告患者层面结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reirradiation (reRT) for locally or regionally recurrent breast cancer is increasingly considered, but practice patterns remain heterogeneous. This study reports results from an international Reirradiation Collaborative Group (ReCOG) survey evaluating contemporary clinical reRT practices and key knowledge gaps in optimal breast reRT approaches. METHODS AND MATERIALS: Radiation oncologists, medical physicists, and dosimetrists with expertise in breast radiation therapy completed a structured ReCOG survey between February 2024 and June 2025. Respondents were asked about patient selection, factors influencing the choice between second breast-conserving therapy and mastectomy, reRT dose-fractionation schedules, planning methods, and knowledge gaps affecting clinical decision making. RESULTS: Thirty-seven respondents participated, from Europe (n = 19), North America (n = 14), and other regions (n = 4), representing 32 identifiable institutions. The most common reasons for not offering reRT included high risk of major side effects from prior radiation therapy such as fibrosis or lymphedema (40%), short relapse interval (33%), or limited life expectancy (17%). Among patients receiving reRT, fibrosis (31%), pain (17%), and arm lymphedema (14%) were reported as the most impactful toxicities on quality of life. Conventional fractionation (45-60 Gy in 1.8 to 2 Gy fractions over 23-30 fractions) was the most frequently selected regimen, followed by moderate hypofractionated schedules (40 Gy in 15 fractions). One respondent reported using twice daily dose of 40 to 50Gy in 1.25 to 1.5Gy fractions. External-beam photon techniques were the predominant modality, with intensity modulated radiation therapy/volumetric modulated arc therapy preferred, while proton therapy and brachytherapy were used selectively. Hyperthermia use was limited (n = 7). Most respondents (80%) performed plan summation when prior DICOM radiation therapy data were available, but specific methods varied. Organs of interest (OOI) dose guidance was most consistently applied for the brachial plexus, heart, lungs, and skin, although thresholds differed widely. The top 3 knowledge gaps identified were as follows: (1) long-term toxicity and oncologic outcome data, (2) standardized and validated OOI dose guidance, and (3) consensus on optimal reRT dose-fractionation schedules, and the scarcity of prospective trials. CONCLUSIONS: This ReCOG survey reveals substantial heterogeneity in breast cancer reRT practices. The identified knowledge gaps highlight the need for standardized clinical guidelines and practical clinical toolsets to support decision making in patient selection, technical planning, and OOI dose guidance to improve outcomes for patients undergoing reRT.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hong L, Poortmans P, Aznar M, et al. Breast Cancer Reirradiation Practice Patterns: An International Survey From the Reirradiation Collaborative Group (ReCOG). Pract Radiat Oncol. 2026. PMID: 42207068. doi:10.1016/j.prro.2026.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。